26 November 2020 in Neurochemical Research
27 March 2015 in Journal of Cardiovascular Pharmacology and Therapeutics
Background: Renalase is a protein that can regulate sympathetic nerve activity by metabolizing catecholamines, while redundant catecholamines are thought to contribute to atherosclerosis (As). Catecholamine release can be facilitated by angiotensin (Ang) II by binding to Ang II type 1 (AT1) receptors. Valsartan, a special AT1 antagonist, can dilate blood vessels and reduce blood pressure, but it remained unclear whether valsartan can promote the stability of atherosclerotic plaque by affecting renalase.Objective: This study examined the tissue distribution of renalase in ApoE−/−mice fed with a high-fat diet and the effect of valsartan on expression of renalase.Methods: ApoE−/−mice were fed with a high-fat diet for 13 or 26 weeks. As a control, 10 C57BL mice were fed with a standard chow diet. After 13 weeks on the high-fat diet, the ApoE−/−mice were randomized (10 mice/group) and treated with valsartan, simvastatin, or distilled water (control group) for an additional 13 weeks accompanied by a high-fat diet.Results: Knockout of ApoE caused a dramatic increase in expression of renalase in mice adipose tissue. With the disturbance of lipid metabolism induced by a high-fat diet, renalase expression decreased in the liver. Renalase can be expressed in smooth muscle cells and M2macrophages in atherosclerotic plaque, and its expression gradually decreases in the fibrous cap during the transition from stable to vulnerable atherosclerotic plaque. Valsartan, an AT1 receptor antagonist, promotes the stabilization of atherosclerotic plaque by increasing the levels of renalase in serum and the expression of renalase in the fibrous cap of atherosclerotic plaque. It also reduces triglyceride levels in serum and increases the expression of renalase in the liver.Conclusions: Renalase may be a potential-related gene of lipid metabolism and As, and it may be the possible molecular target of valsartan to help stabilize atherosclerotic plaque.
1 February 2020 in Arquivos de Neuro-Psiquiatria
Many factors are found to express abnormally in AD patients or animals, such as tumor necrosis factor (TNF)-α8, brain-derived neurotrophic factor (BDNF)9, homocysteine10, and C-reactive protein (CRP)11. BDNF and CRP are both widely studied factors in AD development. Lower BDNF levels were found in AD patients, higher BDNF serum levels were correlated with slower cognitive decline in AD patients12. For CRP, lower levels of CRP were observed in AD patients than the healthy13. Besides, among the factors, the human complement factor H (CFH), which is considered to play an important role in the stimulation of pro-inflammatory responses, has been noticed in AD development14,15. Animal researches showed CFH was down-regulated in AD models16; however in clinical studies, the results are still controversial17. Some researches indicate CFH is abnormally expressed in AD, however others showed no significant difference was found15,18. Similar dispute is also found in levels of CRP. Despite the findings that CRP was decreased in AD patients, a recent study provided opposite results19,20.
1 August 2020 in Materials Science in Semiconductor Processing
1 January 2011 in Dental Materials Journal
Percentage of gutta-percha-filled area (PGFA) was used to investigate the sealing ability of GuttaFlow. A total of 80 mandibular first premolars with single canal were randomly divided into 4 Groups (n=20) according to root canal filling technique and/or material — Group1: cold lateral condensation technique; Group 2: continuous wave condensation technique; Group 3: GuttaFlow; Group 4: GuttaFlow and accessory gutta-percha cones without lateral condensation. The PGFA values of Groups 3 and 4 were significantly higher than those of Groups 1 and 2 (p0.05). It was concluded that GuttaFlow provided superior sealing ability, such that accessory gutta-percha cones became unnecessary when filling root canals with GuttaFlow.